PDS Biotechnology (NASDAQ:PDSB) Receives Buy Rating from HC Wainwright

PDS Biotechnology (NASDAQ:PDSB - Get Free Report)'s stock had its "buy" rating restated by HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $13.00 target price on the stock. HC Wainwright also issued estimates for PDS Biotechnology's Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.01) EPS, FY2026 earnings at ($0.99) EPS, FY2027 earnings at ($1.10) EPS and FY2028 earnings at ($0.92) EPS.

Separately, Wall Street Zen raised PDS Biotechnology from a "sell" rating to a "hold" rating in a research note on Saturday, May 24th.

PDS Biotechnology Trading Down 2.2%

PDS Biotechnology stock traded down $0.04 during mid-day trading on Wednesday, hitting $1.75. The stock had a trading volume of 327,198 shares, compared to its average volume of 495,109. The stock has a 50-day simple moving average of $1.34 and a two-hundred day simple moving average of $1.46. The stock has a market capitalization of $79.99 million, a PE ratio of -1.51 and a beta of 1.27. PDS Biotechnology has a 12 month low of $0.85 and a 12 month high of $4.42. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.04. As a group, sell-side analysts forecast that PDS Biotechnology will post -1.2 EPS for the current year.

Hedge Funds Weigh In On PDS Biotechnology

Hedge funds have recently added to or reduced their stakes in the stock. Armistice Capital LLC bought a new position in shares of PDS Biotechnology during the 1st quarter valued at about $5,259,000. Blair William & Co. IL lifted its holdings in shares of PDS Biotechnology by 63.3% during the 1st quarter. Blair William & Co. IL now owns 257,200 shares of the company's stock valued at $306,000 after purchasing an additional 99,700 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of PDS Biotechnology by 331.0% during the 4th quarter. Renaissance Technologies LLC now owns 100,000 shares of the company's stock valued at $163,000 after purchasing an additional 76,800 shares in the last quarter. Iron Gate Global Advisors LLC bought a new position in shares of PDS Biotechnology during the 1st quarter valued at about $89,000. Finally, Two Sigma Investments LP lifted its holdings in shares of PDS Biotechnology by 273.5% during the 4th quarter. Two Sigma Investments LP now owns 65,732 shares of the company's stock valued at $107,000 after purchasing an additional 48,132 shares in the last quarter. Institutional investors and hedge funds own 26.84% of the company's stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.